Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer
Authors
Keywords
-
Journal
BIODRUGS
Volume 37, Issue 6, Pages 891-899
Publisher
Springer Science and Business Media LLC
Online
2023-09-25
DOI
10.1007/s40259-023-00624-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival improvement for patients with metastatic colorectal cancer over twenty years
- (2023) Fadl A. Zeineddine et al. npj Precision Oncology
- Use of Biosimilar Medications in Oncology
- (2022) Zeina Nahleh et al. JCO Oncology Practice
- Implementing and Optimizing Biosimilar Use at Mayo Clinic
- (2022) Chelsee J. Jensen et al. MAYO CLINIC PROCEEDINGS
- Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study
- (2022) Douglas J. Rupert et al. BIODRUGS
- Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis
- (2022) Xinyi Xu et al. Frontiers in Pharmacology
- Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
- (2022) Xian Xiao et al. Translational Cancer Research
- Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial
- (2022) Claire Verschraegen et al. BIODRUGS
- Real‐world use of IBI305 , a bevacizumab biosimilar, in a tertiary caner‐specialized hospital in China
- (2022) Zhe Chen et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
- (2021) Brian Godman et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey
- (2021) Allison R. Kolbe et al. BIODRUGS
- Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb
- (2021) Jennifer Philippon Booth et al. HOSPITAL PHARMACY
- An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access
- (2021) Natasha B. Leighl et al. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
- Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System
- (2021) Bharati Bhardwaja et al. BIODRUGS
- Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer
- (2021) Whitney Rhodes et al. Future Oncology
- S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients
- (2021) Veena Shankaran et al. JNCI-Journal of the National Cancer Institute
- Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
- (2021) Miguel Angel Calleja et al. European Journal of Hospital Pharmacy-Science and Practice
- Financial toxicity in cancer care: origins, impact, and solutions
- (2021) Hannah R Abrams et al. Translational Behavioral Medicine
- Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans
- (2020) James D. Chambers et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey
- (2020) Alexandre Chan et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review
- (2020) Nour Hisham Al-Ziftawi et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center
- (2020) Mara N Villanueva et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions
- (2020) Charles L Bennett et al. LANCET ONCOLOGY
- Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study
- (2019) Nicholas Thatcher et al. CLINICAL CANCER RESEARCH
- Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review
- (2018) Emily Leonard et al. Journal of Managed Care & Specialty Pharmacy
- Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
- (2016) Tobias Engel Ayer Botrel et al. BMC CANCER
- Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non–Small-Cell Lung Cancer
- (2015) Nikki M. Carroll et al. Journal of Oncology Practice
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search